Articles: ninos.
-
Clinical decision-making after allogeneic stem cell transplantation (HSCT) is partially based on hematopoietic chimerism analysis. Short tandem repeat (STR), the current gold standard for quantitative chimerism analysis, has limited sensitivity. Digital polymerase chain reaction (dPCR) combines precise quantification and high reproducibility with excellent sensitivity (usually ≤ 0.1%) in a wide measurement range. However, the reported dPCR-based chimerism detection methods were developed in non-Chinese cohorts and may not be applicable in a Chinese population. ⋯ Our new system has great repeatability and sensitivity, especially in detecting micro-chimerism and in dual donor samples. It is expected to show good applicability in Chinese transplant patients. Selecting dPCR/STR testing according to each individual's chimerism status facilitates sensitive and accurate analysis, effective early treatment interventions, and relapse monitoring in clinical settings.
-
Randomized Controlled Trial Multicenter Study
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.
Treatment options for patients with advanced neuroendocrine tumors are limited. The efficacy of cabozantinib in the treatment of previously treated, progressive extrapancreatic or pancreatic neuroendocrine tumors is unclear. ⋯ Cabozantinib, as compared with placebo, significantly improved progression-free survival in patients with previously treated, progressive advanced extrapancreatic or pancreatic neuroendocrine tumors. Adverse events were consistent with the known safety profile of cabozantinib. (Funded by the National Cancer Institute and others; CABINET ClinicalTrials.gov number, NCT03375320.).